Skip to main
ETNB
ETNB logo

89bio Inc (ETNB) Stock Forecast & Price Target

89bio Inc (ETNB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

89bio Inc., a clinical-stage biopharmaceutical company, is making significant progress in developing pegozafermin for serious conditions such as nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG), targeting a substantial market with unmet medical needs. The company has reported encouraging clinical trial results that indicate the potential efficacy of pegozafermin, which may lead to favorable regulatory outcomes and future revenue opportunities. Additionally, 89bio's strong financial position, underscored by adequate funding to support ongoing development, bolsters investor confidence and enhances its capacity to navigate the competitive landscape of biopharmaceuticals.

Bears say

89bio Inc exhibits several fundamental vulnerabilities contributing to a negative outlook on its stock. Key risks include the potential failure of its product candidate, pegozafermin, to meet projected commercial revenue estimates, which could be impacted by market size, penetration rates, and pricing strategies. Additionally, the company's ability to secure necessary capital resources for ongoing operations and commercialization efforts remains uncertain, posing further concerns for its financial stability and growth potential.

89bio Inc (ETNB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 89bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 89bio Inc (ETNB) Forecast

Analysts have given 89bio Inc (ETNB) a Buy based on their latest research and market trends.

According to 8 analysts, 89bio Inc (ETNB) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

89bio Inc (ETNB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.